Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 15:2021:8556888.
doi: 10.1155/2021/8556888. eCollection 2021.

SLC41A3 Exhibits as a Carcinoma Biomarker and Promoter in Liver Hepatocellular Carcinoma

Qimeng Chang  1   2 , Yayun Xu  1   2 , Jianfa Wang  1   2 , Hui Jing  1   2 , Longhua Rao  1   2 , Weiguo Tang  1   2 , Ziping Zhang  1   2 , Xubo Wu  1   2
Affiliations

SLC41A3 Exhibits as a Carcinoma Biomarker and Promoter in Liver Hepatocellular Carcinoma

Qimeng Chang et al. Comput Math Methods Med. .

Abstract

Liver Hepatocellular Carcinoma (LIHC) is the fifth widely occurred carcinoma, which is thought to be the second primary contributor of carcinoma-associated death. There are almost 788,000 death tolls worldwide. Solute carrier family 41 member 3 (SLC41A3) is a member of solute carrier family 41, and it is the key point of numerous researches. Our research attempted to explore the links between SLC41A3 and LIHC through public databases. Higher expression of SLC41A3 displayed an intimate association with higher pathological stages and poorer prognosis. GO and KEGG analysis revealed the possible regulatory pathways of SLC41A3. Additionally, we carried out cell functional experiments to determine the expression of SLC41A3 in the cell lines of LIHC, as well as the effects of its silence on cell proliferation, migration, and invasion. Our data showed that SLC41A3 was greatly increased in the cell lines of LIHC. Moreover, silencing SLC41A3 impeded LIHC cell proliferation, migration, and invasion in vitro. Collectively, our study demonstrated that highly expressed SLC41A3 was a probable indication of LIHC occurrence, and SLC41A3 could be regarded as a prospective target in the treatment of LIHC.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Differential expression of solute carrier family 41 family genes in LIHC using the GEPIA database. (a) The expression of SLC41A1 in the neoplasm tissues of LIHC. (b) The expression of SLC41A2 in the neoplasm tissues of LIHC. (c) Dramatical higher expression of SLC41A3 was in LIHC tumor tissues compared to normal tissues. ∗P < 0.05.
Figure 2
Figure 2
Assessment of the relationship between solute carrier family 41 family gene expression and pathological cancer stage in LIHC patients using the GEPIA database. (a) Highly expressed SLC41A1 exhibited a significant relationship with high pathological carcinoma stage. (b) The relationship between the expression of SLC41A2 and pathological carcinoma stage. (c) Highly expressed SLC41A3 displayed an obvious association with high pathological carcinoma stage.
Figure 3
Figure 3
Association between the expression level of solute carrier family 41 family genes and prognosis in patients with LIHC. (a) Highly expressed SLC41A1 presented an obvious association with shorter OS of LIHC patients utilizing the GEPIA database. (b) Lowly expressed SLC41A2 had a significant association with shorter OS of LIHC patients using the GEPIA database. (c) Highly expressed SLC41A3 displayed an obvious relationship with shorter OS of LIHC patients using the GEPIA database. (d) Highly expressed SLC41A3 was greatly related to shorter OS of LIHC patients using the Kaplan-Meier Plotter database.
Figure 4
Figure 4
Enrichment analysis of SLC41A3-coexpression genes in LIHC. (a) To identify GO biological process terms of SLC41A3 involvement. (b) To identify GO cellular component terms of SLC41A3 involvement. (c) To identify GO molecular function terms of SLC41A3 involvement. (d) To identify KEGG pathways of SLC41A3 involvement.
Figure 5
Figure 5
In vitro experimental results of SLC41A3 in LIHC cells. (a) SLC41A3 mRNA expression was higher in LIHC cell lines than normal liver cells. (b) SLC41A3 was silenced by siRNA in HCCLM3 cells. (c) Cell proliferation in LIHC cells transfected with si-SLC41A3. (d, e) Cell invasion and migration abilities in LIHC cells transfected with si-SLC41A3. ∗P < 0.05 and ∗∗P < 0.01.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Qin X. Y., Su T., Yu W., Kojima S. Lipid desaturation-associated endoplasmic reticulum stress regulates _MYCN_ gene expression in hepatocellular carcinoma cells. Cell Death & Disease . 2020;11(1):p. 66. doi: 10.1038/s41419-020-2257-y. - DOI - PMC - PubMed
    1. Tang Y., Zhang Y., Hu X. Identification of potential hub genes related to diagnosis and prognosis of hepatitis B virus-related hepatocellular carcinoma via integrated bioinformatics analysis. BioMed Research International . 2020;2020:19. doi: 10.1155/2020/4251761.4251761 - DOI - PMC - PubMed
    1. Shanker M. D., Liu H. Y., Lee Y. Y., et al. Stereotactic radiotherapy for hepatocellular carcinoma: expanding the multidisciplinary armamentarium. Journal of Gastroenterology and Hepatology . 2021;36(4):873–884. doi: 10.1111/jgh.15175. - DOI - PubMed
    1. Sorlini M., Benini F., Cravarezza P., Romanelli G. Hypoglycemia, an atypical early sign of hepatocellular carcinoma. Journal of Gastrointestinal Cancer . 2010;41(3):209–211. doi: 10.1007/s12029-010-9137-0. - DOI - PubMed
    1. Aravalli R. N. Progress in stem cell-derived technologies for hepatocellular carcinoma. Stem Cells Cloning . 2010;3:81–92. doi: 10.2147/sccaa.s6886. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources